EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Upper age limits for US male human papillomavirus vaccination for oropharyngeal cancer prevention: a microsimulation-based modeling study

Rebecca Landy iD, Gregory Haber, Barry I Graubard, Nicole G Campos, Stephen Sy, Jane J Kim, Emily A Burger iD, Li C Cheung, Hormuzd A Katki iD, Maura L Gillison, Anil K Chaturvedi

JNCI: Journal of the National Cancer Institute · 2023

DOI: 10.1093/jnci/djad009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2023. Verfasst von Rebecca Landy und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA. Hauptthemen laut MEDLINE: Papillomavirus Infections, Papillomavirus Vaccines, Oropharyngeal Neoplasms, Cancer Vaccines. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Intramural Research Program, National Cancer Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Human papillomavirus (HVP)–positive oropharyngeal cancer is the most common HPV-associated cancer in the United States. The age at acquisition of oral HPV infections that cause oropharyngeal cancer (causal infections) is unknown; consequently, the benefit of vaccination of US men aged 27-45 years remains uncertain.

Methods

We developed a microsimulation-based, individual-level, state-transition model of oral HPV16 and HPV16-positive oropharyngeal cancer among heterosexual US men aged 15-84 years, calibrated to population-level data. We estimated the benefit of vaccination of men aged 27-45 years for prevention of oropharyngeal cancer, accounting for direct- and indirect effects (ie, herd effects) of male and female vaccination.

Results

In the absence of vaccination, most (70%) causal oral HPV16 infections are acquired by age 26 years, and 29% are acquired between ages 27 and 45 years. Among men aged 15-45 years in 2021 (1976-2006 birth cohorts), status quo vaccination of men through age 26 years is estimated to prevent 95% of 153 450 vaccine-preventable cancers. Assuming 100% vaccination in 2021, extending the upper age limit to 30, 35, 40, or 45 years for men aged 27-45 years (1976-1994 cohorts) is estimated to yield small benefits (3.0%, 4.2%, 5.1%, and 5.6% additional cancers prevented, respectively). Importantly, status quo vaccination of men through age 26 years is predicted to result in notable declines in HPV16-positive oropharyngeal cancer incidence in young men by 2035 (51% and 24% declines at ages 40-44 years and 45-49 years, respectively) and noticeable declines (12%) overall by 2045.

Conclusion

Most causal oral HPV16 infections in US men are acquired by age 26 years, underscoring limited benefit from vaccination of men aged 27-45 years for prevention of HPV16-positive oropharyngeal cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsPapillomavirus VaccinesOropharyngeal NeoplasmsCancer VaccinesHumansMaleFemaleUnited StatesHuman Papillomavirus VirusesVaccinationHuman papillomavirus 16

Substanzen

Papillomavirus VaccinesCancer Vaccines

Autor:innen und Institutionen

  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
  • Information Technology Laboratory, National Institute of Standards and Technology, Gaithersburg, MD, USA.
  • Center for Health Decision Science, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
  • Department of Health Management and Health Economics, University of Oslo, Norway.
  • Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA.

ORCID-Profile: Rebecca Landy, Emily A Burger, Hormuzd A Katki

Förderung

  • Intramural Research Program
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Landy, R., Haber, G., Graubard, B. I., Campos, N. G., Sy, S., Kim, J. J., Burger, E. A., Cheung, L. C., Katki, H. A., Gillison, M. L., & Chaturvedi, A. K. (2023). Upper age limits for US male human papillomavirus vaccination for oropharyngeal cancer prevention: a microsimulation-based modeling study. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djad009

Vancouver

Landy R, Haber G, Graubard BI, Campos NG, Sy S, Kim JJ, et al. Upper age limits for US male human papillomavirus vaccination for oropharyngeal cancer prevention: a microsimulation-based modeling study. JNCI: Journal of the National Cancer Institute. 2023. doi:10.1093/jnci/djad009

BibTeX
@article{Landy2023,
  author = {Landy, Rebecca and Haber, Gregory and Graubard, Barry I and Campos, Nicole G and Sy, Stephen and Kim, Jane J and Burger, Emily A and Cheung, Li C and Katki, Hormuzd A and Gillison, Maura L and Chaturvedi, Anil K},
  title = {Upper age limits for US male human papillomavirus vaccination for oropharyngeal cancer prevention: a microsimulation-based modeling study},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2023},
  doi = {10.1093/jnci/djad009}
}
Kostenlos starten →